Indberetning af ledende medarbejderes og disses nærtståendes transaktioner i SP Group A/S
Schur Finance a/s, der er nærtstående til Bestyrelsesformand Hans W. Schur (Hans W. Schur er adm. direktør i Schur Finance a/s) har i dag købt 7.123 stk. SPG aktier, fondskode DK0061027356, til kurs 269,47 svarende til DKK 1.919.466,86.
Vedhæftet filFor at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Sampo plc’s share buybacks 05/06/20236.6.2023 07:30:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 06/06/2023 at 08:30 am Sampo plc’s share buybacks 05/06/2023 On 05/06/2023 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)7,94943.63AQEU31,84643.50CEUX13,65043.61TQEX66,55543.52XHELTOTAL120,00043.53 *rounded to two decimals On 29 March 2023, Sampo announced a share buyback programme of up to a maximum of EUR 400 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 3 April 2023, is based on the authorisation granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 4,530,623 Sampo A shares representing 0.89 per cent of the total number of shares in Sampo plc. Details o
IDEX Biometrics – Disclosure of holding - 6 June 20236.6.2023 07:30:00 CEST | Press release
This notice is issued by IDEX Biometrics ASA on behalf of the shareholder mentioned below. Reference is made to the disclosure on 26 May that Robert Keith had lent 42,000,000 shares in connection with the settlement of Tranche 1 in the private placement of shares in IDEX Biometrics on 24 May 2023. The shares have been returned to Mr. Keith. After the return of the shares, Mr. Keith and close relations hold 157,873,873 shares or rights to shares or 12.3% of the total outstanding shares and votes in IDEX Biometrics, based on the share capital after completion of Tranche 1 of the private placement. This notice was published by Erling Svela, Vice president of finance, on 6 June 2023 at 07:30 CET on behalf of IDEX Biometrics ASA on behalf of Robert Keith.
Sercel Awarded Major Contract for a GPR300 Seabed Nodal Solution for Seismic Survey in China6.6.2023 07:30:00 CEST | Press release
Paris, France – June6, 2023 CGG announced today that Sercel has made a major sale of its GPR300 seabed nodal solution to Sinopec, the Chinese oil and gas exploration, refining and distribution company. Over 6,000 nodes will be deployed this month in the Bohai Sea off the east coast of mainland China. Based on Sercel’s breakthrough QuietSeis® MEMS technology, the GPR300 delivers unprecedented broadband signal sensing capability and fidelity, and ultra-quiet performance to enable best-in-class subsurface imaging and outperforms conventional OBN equipment. With its compact and lightweight design, the GPR300 is easy to use whatever the deployment mode. Emmanuelle Dubu, Sercel CEO, said: “We are very pleased to partner with Sinopec once again and to support them in successfully completing this new complex project. On the strength of our in-depth knowledge of the seismic industry and the greater opportunities we see node acquisition bringing in terms of enhanced data quality and insight for
Sleeping better starts here: participate in the webinar of Beter Bed and Dr Sleep6.6.2023 07:30:00 CEST | Press release
On 13 June, Beter Bed, in collaboration with ‘Dr Sleep’, Merijn van de Laar, will be organising a free webinar for everyone keen to improve their sleep. Anyone who sleeps badly one night will notice the difference immediately the next day in terms of mood and focus. Moreover, sleeping badly has an impact on health. As many as one in five Dutch people suffer from some form of sleep deprivation. This webinar is a perfect opportunity for many to change this immediately. The free webinar on 13 June at 8 p.m. will provide more insight into all the factors that influence the quality of sleep. The webinar aims to raise awareness of the impact of poor sleep and motivate viewers to improve sleep quality for a healthier, more energetic and happier life. Participants will learn how to put these steps into practice immediately. Dr Sleep, Merijn van de Laar, explains: “Everything about sleeping better will be dealt with. When do you sleep better, and what happens if your night's sleep is no longer
AccuStem Sciences, Inc. Announces Collaboration Agreement with University Hospitals6.6.2023 07:00:00 CEST | Press release
LONDON and PHOENIX, Ariz., June 06, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today announced the establishment of a joint clinical collaboration agreement with University Hospitals. Per the terms of this agreement, University Hospitals will provide tissue samples with clinical outcomes to AccuStem for research purposes. The scope of the agreement covers a multitude of different cancers but will initially focus on breast cancer cases to support further validation of the StemPrintER test. The goal of the initial project is to build on the strong foundation of data for StemPrintER by demonstrating additional clinical utility beyond identifying patients’ risk of recurrence. This next step is critical for women with early stage breast cancer because there are many tests to determine the need for chemotherapy but there are no genomic tools to inform decisions earlier in the c